INTERNATIONAL JOURNAL OF ADVANCES IN CASE REPORTS

e - ISSN - 2349 - 8005

www.mcmed.us/journal/ijacr

Case Report

THERAPEUTIC DRUG MONITORING IN CRITICAL CARE: EVIDENCE FROM CASE STUDIES

Mary Rejeena S.S

Rajputana College of Pharmacy, Bangalore, Karnataka, India.

ABSTRACT

Therapeutic drug monitoring (TDM) plays a vital role in optimizing pharmacotherapy in critically ill patients, where altered physiology significantly impacts drug pharmacokinetics and pharmacodynamics. In critical care settings, factors such as organ dysfunction, fluid shifts, altered protein binding, and the use of life-support systems can lead to unpredictable drug exposure, increasing the risk of therapeutic failure or toxicity. TDM involves the measurement and interpretation of drug concentrations in biological fluids to individualize dosing regimens and achieve optimal therapeutic outcomes. This approach is particularly important for drugs with narrow therapeutic indices, including antibiotics, anticonvulsants, immunosuppressants, and cardiovascular agents. Case-based evidence has demonstrated the effectiveness of TDM in improving clinical outcomes by enabling dose adjustments tailored to patient-specific conditions. Clinical case studies highlight the role of TDM in preventing toxicity, ensuring adequate drug exposure, and supporting antimicrobial stewardship in critically ill populations. Advances in analytical techniques, pharmacokinetic modeling, and real-time monitoring technologies have enhanced the accuracy and clinical utility of TDM. Despite its benefits, challenges such as limited availability of rapid assays, variability in interpretation, and resource constraints persist. This review explores the principles, clinical relevance, and case-based evidence supporting the use of TDM in critical care, emphasizing its importance in achieving precision pharmacotherapy and improving patient safety.

Key words: Therapeutic drug monitoring; Critical care; Pharmacokinetics; Case-based evidence; Precision dosing.

Corresponding Author: **Mary Rejeena S.S**

Email: rejeena.sanar@gmail.com

Access this article online		
Home page: **http://www.mcmed.us/journal/ijacr**	**Quick Response code**	
Received: 08.02.2026	**Revised**: 28.02.2026	**Accepted**: 31.03.2026

INTRODUCTION

Therapeutic drug monitoring (TDM) has become an essential component of pharmacotherapy in critical care settings, where patients often exhibit significant physiological alterations that affect drug disposition and response. Critically ill patients frequently experience changes in organ function, including hepatic and renal impairment, as well as alterations in fluid balance, plasma protein levels, and tissue perfusion. These factors can lead to unpredictable pharmacokinetics and pharmacodynamics, making standard dosing regimens inadequate or potentially harmful. TDM involves the measurement of drug concentrations in biological fluids, typically blood or plasma, followed by the interpretation of these levels to guide individualized dosing.[1] This approach is particularly important for drugs with narrow therapeutic indices, where small deviations in drug concentration can result in toxicity or therapeutic failure. In critical care, TDM is commonly applied to antibiotics such as vancomycin and aminoglycosides, anticonvulsants, immunosuppressant's, and certain cardiovascular drugs. The integration of TDM into clinical practice allows for dose optimization based on patient-specific variables, thereby improving therapeutic efficacy and minimizing adverse effects. Case-based evidence has provided valuable insights into the application of TDM in real-world clinical scenarios, demonstrating its role in managing complex cases involving sepsis, organ failure, and multi-drug therapy. Furthermore, advances in pharmacokinetic modeling, population-based dosing strategies, and real-time monitoring technologies have enhanced the precision and effectiveness of TDM. Despite these advancements, challenges such as variability in assay availability, delays in obtaining results, and the need for specialized expertise in data interpretation continue to limit its widespread implementation[2]. Additionally, the integration of TDM with pharmacogenomics and digital health tools holds promise for further enhancing individualized therapy. Therefore, understanding the principles and clinical applications of TDM is crucial for optimizing drug therapy in critically ill patients. This review aims to explore the significance of TDM in critical care, supported by case-based evidence, and to highlight emerging trends and future directions in this field.

Therapeutic Drug Monitoring in Critical Care

Therapeutic drug monitoring (TDM) is an essential clinical tool in critical care settings, aimed at optimizing drug therapy by maintaining plasma drug concentrations within a defined therapeutic range. Critically ill patients often exhibit significant variability in drug pharmacokinetics and pharmacodynamics due to altered physiological conditions such as organ dysfunction, hemodynamic instability, and the use of supportive interventions like mechanical ventilation and renal replacement therapy. These factors can lead to unpredictable drug absorption, distribution, metabolism, and excretion, increasing the risk of sub therapeutic exposure or toxicity. TDM is particularly important for drugs with narrow therapeutic indices, significant interindividual variability, or nonlinear pharmacokinetics [3]. Commonly monitored drugs in critical care include antibiotics such as vancomycin and aminoglycosides, antiepileptic's, immunosuppressant's, and certain cardiovascular agents. By measuring drug concentrations at specific time points and adjusting dosing regimens accordingly, TDM helps achieve optimal therapeutic outcomes while minimizing adverse effects. In addition, TDM supports individualized therapy, which is critical in critically ill populations where standard dosing regimens may not be appropriate. Advances in analytical techniques and pharmacokinetic modeling have further enhanced the precision and clinical utility of TDM. Overall, TDM plays a vital role in improving drug efficacy, ensuring patient safety, and supporting evidence-based clinical decision-making in intensive care units.

Table 1: Common Drugs Monitored in Critical Care

Drug Class	Example Drugs	Indication	Therapeutic Range	Common Analytical Methods
Antibiotics	Vancomycin, Aminoglycosides	Sepsis, Infection	10-20 µg/mL	HPLC, Immunoassays
Antiepileptics	Phenytoin, Valproic Acid	Seizures	10-20 µg/mL	HPLC, LC-MS
Immunosuppressants	Cyclosporine, Tacrolimus	Organ transplant rejection	50-200 ng/mL	Immunoassays
Cardiovascular Agents	Digoxin, Lidocaine	Heart failure, Arrhythmias	0.5-2.0 ng/mL	HPLC, Immunoassays

Pharmacokinetic Alterations in Critically Ill Patients

Pharmacokinetic alterations in critically ill patients significantly impact drug disposition and therapeutic outcomes, necessitating individualized dosing strategies. In these patients, physiological changes such as altered organ perfusion, fluid shifts, and inflammation can influence drug absorption, distribution, metabolism, and excretion. For instance, increased capillary permeability and fluid resuscitation can expand the volume of distribution, particularly for hydrophilic drugs, leading to lower plasma concentrations. Hypoalbuminemia, commonly observed in critically ill patients, reduces protein binding and increases the free fraction of drugs, potentially enhancing both therapeutic and toxic effects. Hepatic dysfunction can impair drug metabolism, while renal impairment or augmented renal clearance can respectively decrease or increase drug elimination[4]. Additionally, extracorporeal therapies such as dialysis and extracorporeal membrane oxygenation (ECMO) can further alter drug pharmacokinetics by removing drugs from circulation or changing their distribution. These complex and dynamic changes make it challenging to predict drug behavior using standard dosing regimens. Therefore, TDM becomes an indispensable tool for adjusting doses in real time based on measured drug concentrations. Understanding pharmacokinetic variability in critically ill patients is crucial for optimizing drug therapy and improving clinical outcomes.[5]

Pharmacodynamics Considerations in Critical Care

Pharmacodynamics considerations in critical care are essential for understanding the relationship between drug concentration and therapeutic effect, particularly in the context of altered physiological states. Critically ill patients often exhibit changes in receptor sensitivity, signal transduction pathways, and disease-related factors that can influence drug response. For example, in sepsis, inflammatory mediators can alter receptor expression and function, potentially reducing drug efficacy. The pharmacodynamics targets for many drugs, especially antimicrobials, must be carefully achieved to ensure therapeutic success. Time-dependent antibiotics require maintaining drug concentrations above the minimum inhibitory concentration (MIC), while concentration-dependent drugs rely on achieving high peak concentrations relative to MIC. Failure to achieve these targets can lead to therapeutic failure and the development of resistance. Additionally, organ dysfunction can alter drug sensitivity, increasing the risk of adverse effects[6]. For instance, central nervous system toxicity may occur with certain drugs in patients with renal impairment. TDM plays a critical role in ensuring that pharmacodynamics targets are met by guiding dose adjustments based on measured drug concentrations. Integrating pharmacokinetic and pharmacodynamics principles is essential for optimizing drug therapy in critically ill patients and improving clinical outcomes.

Indications for Therapeutic Drug Monitoring

Therapeutic drug monitoring is indicated in clinical situations where there is a need to optimize drug therapy and minimize the risk of toxicity or therapeutic failure. In critical care settings, TDM is particularly valuable for drugs with narrow therapeutic indices, where small variations in concentration can lead to significant clinical consequences. Drugs with high interindividual variability in pharmacokinetics, such as aminoglycosides and vancomycin, are common candidates for TDM. Additionally, drugs exhibiting nonlinear pharmacokinetics, where dose changes do not result in proportional changes in plasma concentration, require careful monitoring. TDM is also indicated in patients with altered physiological states, such as renal or hepatic dysfunction, where drug metabolism and excretion may be impaired.[7] In critically ill patients receiving multiple medications, TDM helps identify and manage potential drug–drug interactions. Furthermore, TDM is useful in assessing patient adherence, evaluating therapeutic response, and guiding dose adjustments in special populations such as pediatric or geriatric patients. Overall, the appropriate use of TDM ensures safe and effective drug therapy, particularly in complex clinical scenarios encountered in critical care.

Figure 1: Indications for Therapeutic Drug Monitoring

Sampling Strategies and Analytical Techniques in TDM

Accurate sampling strategies and reliable analytical techniques are fundamental to the effectiveness of therapeutic drug monitoring. The timing of sample collection is critical, as it must correspond to specific pharmacokinetic parameters such as peak and trough concentrations. For example, trough levels are often measured just before the next dose to assess steady-state drug concentrations, while peak levels are measured shortly after drug administration to evaluate maximum exposure. In critically ill patients, achieving steady-state conditions may be challenging due to dynamic physiological changes, requiring careful interpretation of results. Analytical techniques used in TDM include immunoassays, high-performance liquid chromatography (HPLC), and liquid chromatography–mass spectrometry (LC-MS), each offering varying degrees of sensitivity and specificity[8]. Advances in analytical technology have improved the accuracy, speed, and reliability of drug concentration measurements. Point-of-care testing and biosensor-based methods are emerging as rapid alternatives for real-time monitoring in critical care settings. Ensuring proper sample handling, storage, and processing is essential to avoid errors that could affect clinical decision-making. Overall, precise sampling and robust analytical methods are crucial for the successful implementation of TDM and optimization of drug therapy[9].

Role of Pharmacokinetic Modeling and Dose Optimization

Pharmacokinetic modeling plays a crucial role in optimizing drug dosing in critically ill patients by integrating patient-specific data with mathematical models to predict drug behavior. Traditional dosing approaches often fail to account for the variability seen in critical care settings, making model-based dosing strategies more reliable. Population pharmacokinetic models use data from similar patient groups to estimate dosing requirements, while Bayesian forecasting incorporates individual patient data, such as measured drug concentrations, to refine dosing predictions in real time. These models enable clinicians to achieve target drug concentrations more accurately, improving therapeutic outcomes and reducing the risk of toxicity[10]. Dose optimization through pharmacokinetic modeling is particularly important for antibiotics, where achieving appropriate exposure is critical for efficacy and resistance prevention. Advances in computational tools and software have made pharmacokinetic modeling more accessible in clinical practice. Integration of these tools with electronic health records further enhances their utility by enabling automated dose adjustments based on patient data. Overall, pharmacokinetic modeling represents a powerful approach to individualizing drug therapy in critical care[11].



Figure 2: Role of Pharmacokinetic Modeling and Dose Optimization

Case Reports in Renal and Hepatic Dysfunction

Case reports involving patients with renal and hepatic dysfunction highlight the critical role of therapeutic drug monitoring in managing altered drug pharmacokinetics. In patients with renal impairment, reduced drug clearance can lead to drug accumulation and increased risk of toxicity, necessitating dose adjustments based on TDM results. For example, aminoglycosides require careful monitoring to avoid nephrotoxicity and ototoxicity. Conversely, augmented renal clearance in certain critically ill patients may result in subtherapeutic drug levels, requiring higher doses to achieve therapeutic targets[12]. Hepatic dysfunction affects drug metabolism, particularly for drugs extensively metabolized by the liver, leading to prolonged drug half-life and increased risk of adverse effects. Case-based evidence demonstrates that TDM-guided dose adjustments can significantly improve patient outcomes by maintaining drug concentrations within the therapeutic range. These cases also emphasize the importance of individualized therapy and continuous monitoring in patients with organ dysfunction. Overall, TDM provides valuable insights into drug behavior in complex clinical scenarios and supports safe and effective pharmacotherapy[13].

Role of Clinical Pharmacists in TDM Implementation

Clinical pharmacists play a vital role in the successful implementation of therapeutic drug monitoring in critical care settings. Their expertise in pharmacokinetics, pharmacodynamics, and drug interactions enables them to interpret TDM data accurately and recommend appropriate dose adjustments. Clinical pharmacists are involved in designing individualized dosing regimens, selecting appropriate sampling times, and ensuring the proper use of analytical techniques. They also collaborate with physicians and other healthcare professionals to optimize drug therapy and improve patient outcomes. In addition, clinical pharmacists contribute to patient education and support adherence to therapy[14]. Their involvement in antimicrobial stewardship programs further enhances the rational use of antibiotics and reduces the risk of resistance. Clinical pharmacists also play a key role in pharmacovigilance by identifying and reporting adverse drug reactions. Overall, their contribution is essential for maximizing the benefits of TDM and ensuring safe and effective drug therapy in critically ill patients.

Integration of TDM in Antimicrobial Stewardship Programs

The integration of therapeutic drug monitoring into antimicrobial stewardship programs is essential for optimizing antibiotic therapy and combating antimicrobial resistance. TDM enables clinicians to achieve optimal drug exposure by adjusting dosing based on pharmacokinetic and pharmacodynamic parameters. This is particularly important for antibiotics with narrow therapeutic windows or significant variability in drug disposition. By ensuring that drug concentrations remain above the minimum inhibitory concentration, TDM enhances therapeutic efficacy and reduces the risk of treatment failure. Additionally, TDM helps prevent toxicity by avoiding excessive drug exposure. In critically ill patients, where physiological changes can significantly alter drug pharmacokinetics, TDM is a valuable tool for individualized therapy[15]. The use of TDM in antimicrobial stewardship programs supports evidence-based decision-making and promotes the rational use of antibiotics. Advances in analytical techniques and pharmacokinetic modeling have further improved the effectiveness of TDM in this context. Overall, the integration of TDM into antimicrobial stewardship programs is a key strategy for improving patient outcomes and addressing the global challenge of antimicrobial resistance.

Future Perspectives in Therapeutic Drug Monitoring

The future of therapeutic drug monitoring is poised for significant advancement, driven by innovations in technology, data analytics, and personalized medicine. Emerging techniques such as point-of-care testing and biosensor-based monitoring are enabling real-time assessment of drug concentrations, facilitating rapid clinical decision-making. The integration of artificial intelligence and machine learning algorithms is enhancing the ability to predict drug behavior and optimize dosing regimens based on patient-specific data. Advances in pharmacogenomics are also contributing to the development of more precise and individualized therapeutic strategies[16]. Additionally, the incorporation of digital health technologies, such as wearable devices and electronic health records, is improving the collection and analysis of patient data. These developments are expected to enhance the accuracy, efficiency, and accessibility of TDM in clinical practice. As healthcare systems continue to adopt precision medicine approaches, TDM will play an increasingly important role in optimizing drug therapy and improving patient outcomes. Overall, the future of TDM holds great promise for advancing personalized pharmacotherapy and enhancing the quality of care in critical care settings.

CONCLUSION

Therapeutic drug monitoring (TDM) has established itself as an indispensable component of pharmacotherapy in critical care, addressing the complexities and variability inherent in managing critically ill patients. The dynamic physiological changes observed in these patients, including altered organ function, fluid imbalances, and the use of life-support interventions, significantly impact drug pharmacokinetics and pharmacodynamics, making standard dosing regimens often inadequate. In this context, TDM provides a robust framework for individualized drug therapy by enabling clinicians to measure drug concentrations, interpret them in relation to therapeutic targets, and adjust dosing regimens accordingly. This approach not only enhances therapeutic efficacy but also minimizes the risk of adverse drug reactions, particularly for drugs with narrow therapeutic indices or high interindividual variability. Evidence from case studies further underscores the clinical value of TDM, demonstrating its role in optimizing treatment outcomes in complex scenarios such as sepsis, renal and hepatic dysfunction, and multi-organ failure. These real-world insights highlight the importance of TDM in achieving precise drug exposure, preventing toxicity, and improving patient safety. Moreover, the integration of pharmacokinetic and pharmacodynamic principles into TDM practices allows for a more comprehensive understanding of drug behavior in critically ill populations. The involvement of clinical pharmacists has further strengthened the implementation of TDM by ensuring accurate interpretation of data and facilitating collaborative decision-making within multidisciplinary healthcare teams. Advances in analytical techniques, pharmacokinetic modeling, and digital health technologies have significantly improved the precision, accessibility, and efficiency of TDM, paving the way for more proactive and responsive therapeutic strategies. Additionally, the incorporation of TDM into antimicrobial stewardship programs has contributed to the rational use of antibiotics, reducing the risk of antimicrobial resistance while maintaining optimal therapeutic outcomes. Despite these advancements, challenges such as variability in sampling practices, limited availability of rapid testing methods, and the need for standardized guidelines persist. Addressing these limitations requires continued research, education, and investment in healthcare infrastructure. Looking ahead, the integration of artificial intelligence, real-time monitoring systems, and pharmacogenomic data is expected to further enhance the capabilities of TDM, aligning it with the principles of precision medicine. In conclusion, TDM represents a critical tool in modern critical care practice, supported by strong case-based evidence, and holds significant potential for improving clinical outcomes, ensuring patient safety, and advancing individualized pharmacotherapy in complex clinical settings.

REFERENCES

1. Morales Castro, D., Dresser, L., Granton, J., & Fan, E. (2023). Pharmacokinetic alterations associated with critical illness. *Clin Pharmacokinet*, 62, 209–220.
2. Koch, B. C. P., Muller, A. E., Hunfeld, N. G. M., De Winter, B. C. M., Ewoldt, T. M. J., Abdulla, A., et al. (2022). Therapeutic drug monitoring of antibiotics in critically ill patients: Current practice and future perspectives with a focus on clinical outcome. *Therapeutic Drug Monitoring*, 44, 11–18.
3. Gabunia, L., Gorgaslidze, N., & Sulashvili, N. (2025). Pharmacotherapy in critical care medicine. *Association for Science*.
4. Muolokwu, C. E., Tagoe, B., Attah, M. M., & Amponsah, S. K. (2025). Drug disposition in critical care patients. *281–304*.
5. Abidi, E., El Nekidy, W. S., Atallah, B., Al Zaman, K., Ghisulal, P., El Lababidi, R., et al. (2023). Sustaining life versus altering life-saving drugs: Insights to explain the paradoxical effect of extracorporeal membrane oxygenation on drugs. *JCM*, 12, 3748.
6. Roger, C., Koulenti, D., Novy, E., Roberts, J., & Dahyot-Fizelier, C. (2025). Optimization of antimicrobial therapy in critically ill patients, what clinicians and researchers must know. *Anaesthesia Critical Care & Pain Medicine*, 44, 101561.
7. Ali, A., & Abdel-Rahman, M. (2021). Therapeutic drug monitoring: Fundamentals, and optimization.
8. Flanagan, R., Cuypers, E., Maurer, H., & Whelpton, R. (2020). Therapeutic drug monitoring. *479–504*.
9. Taddeo, A., Prim, D., Bojescu, E-D., Segura, J-M., & Pfeifer, M. E. (2020). Point-of-care therapeutic drug monitoring for precision dosing of immunosuppressive drugs. *The Journal of Applied Laboratory Medicine*, 5, 738–761.
10. Jager, N. G. L., Van Hest, R. M., Xie, J., Wong, G., Ulldemolins, M., Brüggemann, R. J. M., et al. (2020). Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. *Journal of Antimicrobial Chemotherapy*, 75, 2641–2649.
11. Roggeveen, L. F., Guo, T., Driessen, R. H., Fleuren, L. M., Thoral, P., Van Der Voort, P. H. J., et al. (2020). Right dose, right now: Development of AutoKinetics for real-time model informed precision antibiotic dosing decision support at the bedside of critically ill patients. *Front Pharmacol*, 11, 646.
12. Charkviani, M., Brown, C. S., & Barreto, E. F. (2025). Drug dosing in kidney dysfunction. In *Oxford University* (pp. 361–370).
13. Ferreira, V., Vincelette, C., & Mathieu, A. (2021). Joint efforts to ensure evidence-based decisions by clinicians in drug adjustment for chronic liver disease populations. *Hepatol Commun*, 5, 713–714.
14. König, C., Kluge, S., & Wicha, S. G. (2020). Therapeutic drug monitoring of antiinfectives in intensive care unit patients—what's new? *Dtsch Med Wochenschr*, 145, 1764–1769.
15. Rafeh, W. R., Abdelraouf, K., Haddad, N., Rizk, N., & El-Yazbi, F. A. (2020). Antimicrobial therapeutic drug monitoring. In *Bentham Science* (pp. 263–297).
16. Gupta, N., & Babu, M. (2025). Artificial intelligence and machine learning in therapeutic drug monitoring: Revolutionizing dosing and clinical decision support. *Int J Curr Res Med Sci*, 11, 63–77.

Cite this article:
Mary Rejeena S.S (2026). Therapeutic Drug Monitoring in Critical Care: Evidence from Case Studies. *International Journal of Advances in Case Reports*, 13(1), 15-20.